ESG

A new report reveals a looming crisis: rising healthcare costs will consume more than 100% of Social Security benefits for future generations of retirees.

A new survey reveals 84% of firms doubt they can pass an AI compliance audit, exposing a massive security gap as autonomous agent adoption surges.

A landmark deal sees US tech giant CrowdStrike partner with Aramco to build a national cybersecurity defense, securing Saudi Arabia's AI-driven future.

With backing from top VCs, Angitia Biopharmaceuticals is accelerating its novel treatments for osteoporosis and rare bone disorders. Here's why it matters.

Despite product withdrawals, a lack of regulation and the long latency of asbestos-related diseases mean the danger from talc exposure is far from over.

Pluristyx and Solesis launch a 'three-in-one' kit with nearly 100% efficiency in iPSC transfection, tackling a major bottleneck in organoid research.

A new study reveals Exicure's burixafor mobilizes stem cells in one hour, promising to streamline cancer treatment and unlock future gene therapies.

For its tenth straight Games, Technogym will equip Milano Cortina 2026 with AI-driven gear, cementing its legacy as the force behind athletic excellence.

New data reveals an AI-powered system can map and guide heart arrhythmia treatment in minutes with zero fluoroscopy, heralding a new era of safety and speed.

With major drug approvals on the horizon, Nuvalent's leadership will detail its strategy for its next-gen cancer therapies at an influential investor summit.

VectorY Therapeutics adds seasoned biotech architect Kevin Pojasek to its board, signaling a strategic push to accelerate its novel therapies for ALS and Alzheimer's.

As it enters its tenth year, the Zephyr RTOS adds Schneider Electric and others, signaling a major push for standardization and security in a regulated IoT world.

A new report reveals how GLP-1 drugs are accelerating a major healthcare shift in the Gulf, turning metabolic health into a core economic and policy issue.

After years of losses, the electric vehicle maker projects its first-ever adjusted quarterly profit, signaling a new era of financial discipline.

After conquering the US, the AI finance app is back on home turf. But can its playful 'roast mode' succeed in a crowded British FinTech market?

Positive study results for Alvotech's Entyvio biosimilar could disrupt the IBD market, promising lower costs for a blockbuster chronic care treatment.

Bahrain's hospitality giant leverages five decades of experience to challenge the institutional catering sector with a new, tech-driven, large-scale operation.

Kenmare Resources unveils its upgraded Moma Mine, a critical global titanium source, as it pivots from heavy spending to cash generation.

Everest Medicines bets big on MT1013, a novel dual-action drug poised to transform treatment for millions with chronic kidney disease complications.

Sila Realty Trust sets its 2025 earnings date. Investors are watching to see if its strategic acquisitions and dividend policy signal strength for the sector.